CURRICULUM VITAE
Stanislaw R. Burzynski, M.D., Ph.D.

ACADEMIC TRAINING, CERTIFICATION AND LICENSURE

Texas State Board of Medical Examiners
License to Practice Medicine, 1973
Baylor College of Medicine, Houston, Texas
ECFMG Certificate, 1971
Medical Academy, Lublin, Poland
M.D. with Distinction, 1967
Ph.D. (Biochemistry), 1968

POSITIONS HELD

Visiting Professor of Neuro-Oncology, Capital University in Beijing
Beijing, China, 2012 to present
Visiting Professor of Neuro-Oncology, Beijing Tiantan Hospital
Beijing, Tiantan, 2012 to present
Visiting Professor, Linyi People's Hospital
Linyi City, China, 2012 to present
President, Burzynski Research Institute Inc.
Houston, TX, 1983 to present
President, Burzynski Clinic
Houston, TX, 1977 to present
Assistant Professor, Baylor College of Medicine
Houston, Texas, 1972-1977
Research Associate, Baylor College of Medicine
Houston, Texas, 1970-1972
Intern and Resident, Medical Academy, Internship in the Departments of Surgery, Internal Medicine, Pediatrics, Obstetrics and Gynecology, and Residency in the Department of Internal Medicine
Lublin, Poland, 1967-1970
Teaching Assistant, Medical Academy, Department of General Chemistry
Lublin, Poland, 1962-1967
Research Worker, Medical Academy, Department of General Chemistry
Lublin, Poland, 1961-1962

SCIENTIFIC AND PROFESSIONAL MEMBERSHIPS

American Academy of Anti-Aging Medicine
American Academy of Medical Ethics.
American Association for Advancement of Science
American Association for Cancer Research
American Association of Pharmaceutical Scientists
American Chemical Society
American Diabetes Association
American Medical Association
European Association for Neuro-Oncology
Harris County Medical Society
International Union of Pure and Applied Chemistry
New York Academy of Sciences
Parenteral Drug Association
Society for Neuro-Oncology
Society for Neuroscience
Texas Medical Association
The Royal Society of Medicine (U.K.)
The Society of Sigma Xi
World Medical Association
World Society of Anti-Aging Medicine

RESEARCH SUPPORT
National Cancer Institute Grantee, 1974-1977
Baylor College of Medicine Grantee, 1976
West Foundation Grantee, 1975
Medical Academy (Lublin, Poland) Grantee, 1962-1967

HONORS AND AWARDS
Lifetime Achievement Award from the Academy of Comprehensive Integrative Medicine, Ft. Worth, TX, March, 2012
The Linus Pauling Award, October, 2008, ACAM
The Linus Pauling Award, February, 2008, Orthomolecular Health-Medicine
The Order of Merit of the President of Poland – Officer's Cross, October, 2004
Decoration of Polish Medical Association, November, 2001
The Order of Saint Brigida – Grand Cross with Star, November, 2001
The Order of Saint Stanislas – Grand Cross with Star, November, 2000
The Order of Reconciliation – November, 2000
The Cross Virtus Nobilitat, June, 1999
The Wisdom Award of Honor, December, 1998
The Medal of the President of City of Lublin, Poland, December, 1998
The Order of Saint Stanislas- Commander's Cross with Star, December, 1997
The Lady Liberty Award, July, 1997
The Gold Medal from the American Institute of Polish Culture for outstanding achievements in the field of medicine and discovery of anti-cancer drugs antineoplastons, Miami, FL, February, 1997
The Medal "Heart for Hearts" for saving human lives, Lublin, Poland, August, 1997
The Memorial Medal of Zamoyski's Lyceum in appreciation of outstanding contribution to increase scientific ranking of the school, Lublin, Poland, November, 1997
The Heritage Award by Polish American Congress in recognition of extraordinary achievement in the research, treatment, and prevention of cancer, Chicago, IL, October, 1993.
Special Medal from the Polish government's Institute for Drug Research and Control for achievement in the field of cancer research, Bialvstok, Poland, September, 1989
Honorable Membership in the Academia del Medeterraneo, Rome, Italy, 1984
Recipient of commendation for Dedicated Service and for Personal Contribution made in the Advancement of Medical Education, Research and Health Care, Baylor College of Medicine, Houston, TX, April, 1977
Recipient of Medical Doctor Diploma with Distinction, Medical Academy, Lublin, Poland, 1967
Co-winner of the prize for best paper presented at the 7th Conference of Polish Medical Student Research Societies, Poznan, Poland, 1966.
The Hereditary Title of Count

HONORABLE BIOGRAPHY
Biography published in Marquis, Who's Who in the World, 8th through 26th editions
Biography published in Marquis, Who's Who in America, 51st through 65th editions
Biography published in Marquis, Who's Who in Science and Engineering, 2nd through 6th editions
Biography published in Marquis, Who's Who in Medicine and Healthcare, 1st through 6th editions
Biography published in Marquis, Who's Who in Emerging Leaders in America, 1st edition
Biography published in Marquis, Who's Who Frontiers of Science and Technology, 2nd edition
Biography published in American Men and Women of Science, 13th Edition, Jacques Catell Press

CHAIRMAN OF SCIENTIFIC SESSIONS AT INTERNATIONAL MEETINGS

Dubai Congress on Anti-Aging & Aesthetic Medicine (DCAAAM), Dubai, UAE, 2008
1st Anti-Aging International Symposium and Exposition, Tokyo, Japan, 2006
International Conference in Integrative Medicine, Seattle, Washington, U.S.A, 1999
Comprehensive Cancer Care I Conference, Washington, D.C., U.S.A., 1998
18th International Congress of Chemotherapy, Stockholm, Sweden, 1993
17th International Congress of Chemotherapy, Berlin, Germany, 1991
9th International Symposium on Future Trends in Chemotherapy, Geneva, Switzerland, 1990
10th Congress of the Polish Pharmacological Society, Bialystok, Poland, 1989
8th International Symposium on Future Trends in Chemotherapy, Tirrenia, Italy, 1988
10th International Congress of Pharmacology, Sydney, Australia, 1987

INVITED LECTURES (given since 1988)

"Personalized targeted cancer therapy revolution." Keynote Speaker. Presented at the 8th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies Expo, and the 2nd Annual Asia-Pacific Anti-Aging Medicine Summit, Beijing, China, October 25, 2013.

"Clinical trials with Antineoplastons. Long-term survival and quality of life." Keynote Speaker. Presented at the 8th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies Expo, and the 2nd Annual Asia-Pacific Anti-Aging Medicine Summit, Beijing, China, October 26, 2013.

"Antineoplastons, chemistry, mechanism of action, design, and criticism of clinical trials." Keynote Speaker. Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

"Prospective clinical trials with antineoplastons for inoperable brain tumors in children." Keynote Speaker. Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

"Phase 2 prospective clinical trials for inoperable brain tumors in adults." Keynote Speaker. Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

"Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in children." Keynote Speaker. Presented at the Philippine Society of Pediatric Oncology 2012 Annual Convention in Ilo ilo, Philippines, October 27, 2012.

"Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Update." Presented at the Makati Medical Center in Manila, Philippines, October 25, 2012.

"Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in children." Keynote Speaker. Presented at St. Lukes Medical Center in Manila, Philippines, October 24, 2012.

"Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in adults." Keynote Speaker. Presented at St. Lukes Medical Center in Manila, Philippines, October 24, 2012.

"Phase II clinical trials of Antineoplastons in pediatric brain tumors and adult brain tumors." Keynote Speaker. Presented at the "2012 Shanghai World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies Expo (A4MC-2012)," at the Shanghai World Expo Exhibition & Convention Center in Shanghai, China, October 18, 2012.

"The future is full of hope: Cancer treatment based on genomic testing." Keynote Speaker. Presented at the "Hope for the Hopeless Conference," at the American Airlines Training & Conference Center in Ft. Worth, TX, March 9, 2012.

"Molecular Profiling in Oncology Practice: The Results of Treatment in a Group of 1,633 Patients." Presented at "BIT's 4th Annual World Cancer Congress – 2011," Dalian, China, May 24, 2011.

"Epigenomic Approach to Cancer Treatment." Keynote Speaker. Presented at the "45th Annual Meeting of the American Academy of Environmental Medicine," San Diego, CA, October 21, 2010.

"Genomic and Epigenomic Principles of Cancer Treatment." Keynote Speaker. Presented at the "10th Scientific Meeting of the Japanese Society of Anti-Aging Medicine," Kyoto, Japan, June 12, 2010.

"Genomic and Epigenomic Principles of Cancer Treatment." Presented for 50 doctors at Keiko University, Tokyo, Japan, June 9, 2010.

"Genomic and Epigenomic Principles of Cancer Treatment." Presented for 10-20 doctors at Tokai University, Tokyo, Japan, June 8, 2010.

"Antineoplastons." Presented for Antineoplastons Study Group of Japan, Tokyo, Japan, May 13, 2009.

"Mechanisms of Anti-Tumor Activity in Synthetic Antineoplastons." Presented for Antineoplastons Study Group of Japan, Tokyo, Japan, May 13, 2009.

"Practical Application of Gene Silencing Theory of Aging. Life Extension in Animals and Human Clinical Trials." Presented at the "Dubai Congress on Anti-Aging & Aesthetic Medicine (DCAAAM)," Dubai, UAE, 2008

"Antineoplastons and Targeted Gene Therapy." Presented at the "ACAM Las Vegas," Las Vegas, Nevada, October 15-19, 2008

"Genome, Epigenome and Aging." Presented at the "First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies," Estoril, Portugal, May 29-31, 2008

"Personalized Cancer Treatment in Genomics Era." Presented at the "First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies," Estoril, Portugal, May 29-31, 2008

"Anti-Aging Peptides – A New Frontier in Healing." Presented at the "2008 Orthomolecular Health-Medicine conference," San Francisco, CA, February 2008.

"Antineoplaston Peptides in Treating Cancer." Presented at the "2008 Orthomolecular Health-Medicine conference," San Francisco, CA, February 2008.

"Personalized Cancer Treatment." Presented at the "2007 Total Health and Recovery Expo" in The Woodlands, Texas, October 20, 2007

"Cancer Treatment in Genomics Era." Hosted by the Lions Health First Foundation, at the Hilton in Las Vegas, Nevada, September 15, 2007

"The Genetic Solution for Anti-Aging." Presented at the "Healthy Directions Conference," hosted by Dr. Julian Whitaker at the Marriott Westchase in Houston, Texas, January 6, 2007

"The Genetic Solution for Anti-Aging." Presented at 11th Cruising for Health and Wealth, January 2006

"New Cancer Treatments and Anti-Aging Regimens." Presented at the "Polish Club of Leisure World," in Laguna Woods, California, March 13, 2005

"Mechanizmy I profilaktyka genetycznego starzenia (Mechanisms and Prevention of Genetic Aging)." Presented at the "Ogolnoeuropejska Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Neurologicznego," in Lublin, Poland, September (wrzesień) 22-25, 2004

"Regulation of Gene Expression in Cancer and Aging." Presented at "Innovations in Complementary/Integrative Healthcare," in Phoenix, Arizona, September 5-7, 2003

"Treatment of Cancer with Antineoplastons: Effect on Genes and Protein Metabolism." Presented at the "12th Annual Scientific Symposium," in Orlando, Florida, August 27-31, 2003

"Gene Silencing in Cancer and Aging". Presented at Graduation Ceremony: Ultrasound Diagnostic School, November 15, 2002

"Antineoplaston Treatment of Cancer – Results of American and Japanese Clinical Trials." Presented at ABEIM – A Cancer Symposium, Fort Worth, Texas, 2002

"Antineoplaston Cancer Treatment – Theory and Results"; "Cancer and Aging – The Connection"; "Controlling the Key Aging Process of Methylation and Acetylation with the New Category of Anti-Aging Compounds and Antineoplastons." Presented at the 6th International Symposium on Anti-Aging Medicine, Costa Rica, Los Suenos, August 23-24, 2002

"Treatment and Prevention of Cancer with Antineoplastons," Presented in Santiago, Chile, July 3, 2002

"Antineoplastons –Theory and Treatment," Presented at Seminar for Physicians: Sanoviv, Baja California, June 13, 2002
"Treatment of Brain Tumors with Antineoplastons A10 and AS2-1." Presented at Hyman-Newman Institute for Neurology and Neurosurgery, Beth Israel Hospital, New York, August 22, 2001
"Treatment of Brain Tumors with Antineoplastons A10 and AS2-1", Presented at Therapeutic Good Administration (TGA) of Australia, Canberra, Australia, July 17, 2001
"Antineoplastons." Presented at Polish Medical Association, Warsaw, Poland, November 22, 2000.
"Treatment of Cancer with Antineoplastons." Presented at Symposium organized by People Against Cancer in Stuttgart and Munich, Germany, for General Audience, November, 1999
"Antineoplastons: A Breakthrough in Cancer Therapy." Presented at Manila Doctors Hospital, Manila, The Philippines, November 9, 1998
"The New Breakthrough in Cancer." Presented at Marian Cancer Foundation, Manila, The Philippines, November 6, 1998
"Antineoplastons." Presented at "Surviving Cancer." Westminster Central Hall, London, U.K., November 15, 1997
"Antineoplastons: Theory and Clinical Trials." Presented at Medical Academy, Lublin, Poland, November 7, 1997
"Biochemical Defense System." Presented at Medical Academy, Lodz, Poland, July 24, 1992
"Treatment of AIDS and HIV Infection with Antineoplastons AS2-1". Presented at Search Alliance, Los Angeles, California, November 20, 1991
"Cancer, AIDS and the other Immune System". Presented at Foundation for the Advancement of Innovative Medicine, New York, NY, October 26, 1991
"Antineoplastons." Presented at World Research Foundation Congress, Los Angeles, California, October 7, 1990
"Antineoplastons—New Methods of Cancer Treatment." Presented at Polish Pharmacological Society, Lublin, Poland, August 29, 1989
"Clinical Results of Antineoplaston Therapy." Presented at Kurume University School of Medicine, Kurume, Japan, April 9, 1988
"Mechanism of Action of Antineoplaston A10 and Experimental Data." Presented at Kurume University School of Medicine, Kurume, Japan, April 8, 1988
"Isolation, Purification and Synthesis of Antineoplastons." Presented at Kurume University School of Medicine, Kurume, Japan, April 8, 1988

EDITORIAL POSITIONS

Reviews on recent clinical trials, Bentham Science Publishers, Editor-In-Chief (Current).

BOOK CHAPTERS, MONOGRAPHS AND ARTICLES BY S.R. BURZYNSKI AND ASSOCIATES

1 Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Long-term survival (over 13 years) in a child with recurrent diffuse pontine gliosarcoma: the case report. Journal of Pediatric Hematology/Oncology 2013 (in press).

2 Patil, S.S., Mrowczynski, E., Grela, K., Burzynski, S.R. Phenylacetylglutaminate in combination with phenylbutyrate effectively inhibits growth of brain tumor cells in vitro. Neuro-Oncology 2012;14(Suppl. 3):iii16.

3 Patil, S.S., Burzynski, S.R., Mrowczynski, E., Grela, K., Chittur, S.V. Phenylacetylglutaminate and phenylacetate in combination upregulate VDUP1, cause cell cycle blockade and apoptosis in U87 glioblastoma cells. Journal of Cancer Therapy 2012;3:192-200.

4 Paleolog, J., Strachecka, A., Burzynski, S.R., Olszewski, K., Borsuk, G. The larval diet supplemented with sodium phenylacetylglutaminate influences the worker cuticle proteolytic system in honeybees (Apis mellifera). Journal of Apicultural Science 2011;55(2):73-83.

5 Burzynski, S.R, Nagy-Kubove, E. Treatment of esthesioneuroblastoma and non-small cell lung cancer with phenylbutyrate. Journal of Cancer Therapy 2011;2:518-522.

6 Burzynski, S.R, Marquis, A., Nagy-Kubove, E., Janicki, T.J. Successful treatment of recurrent triple-negative breast cancer with combination of targeted therapies. Journal of Cancer Therapy 2011;2:372-376.

7 Burzynski, S.R, Weaver, R.A., Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S. OT-15. Preliminary results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas. Neuro-Oncology 2010;12(Suppl. 4):iv72.

8 Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. CB-15. Targeting microRNAs in glioma cells with antineoplastons. Neuro-Oncology 2010;12(Suppl. 4):iv10.

9 Burzynski, S.R, Weaver, R.A., Janicki, T., E, Szymkowski, B., Acelar, S.S., Burzynski, G.S. A phase II study of antineoplaston A10 and AS2-1 injections in children with low-grade astrocytomas. Neuro-Oncology 2010;12(6):ii95.

10 Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells. Neuro-Oncology 2010;12(6):ii87.

11 Weaver, R.A., Szymkowski, B., Burzynski, S.R. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP). Neuro-Oncology 2009;11:923.

12 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S. Phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma: Protocol BC-BT-11. Neuro-Oncology 2009;11:951.

13 Burzynski, S.R. The coming pandemic of liver cancer: In search of genomic solutions. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume XI;2009.

14 Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animal testing and human clinical trials. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume XI;2009.

15 Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells. Neuro-Oncology 2008;10:1148.

16 Burzynski, S., Weaver, R., Janicki, T., Szymkowski, B., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma. Neuro-Oncology 2008;10:1067.

17 Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints, leading to apoptosis in human glioblastoma cells. Neuro-Oncology 2008;10:786.

18 Burzynski, S., Weaver, R., Janicki, T., Burzynski, G., Samuel, S., Szymkowski, B. Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report. Neuro-Oncology 2008; 10:821.

19 Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S. Phase II study of antineoplastons A10 and AS2-1 (ANP) in children with optic pathway glioma: A preliminary report. Neuro-Oncology 2008;10:450.

20 Burzynski, S.R. The genes of life. Farmapress Publishers, 2008.

21 Burzynski, S.R. Genomic approach to cancer treatment. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume X; 2008;37-44.

22 Burzynski, S.R. Recent clinical trials in diffuse intrinsic brainstem glioma. Cancer Therapy 2007;5, 379-390.

23 Burzynski, S.R., Weaver, R., Szymkowski, B. A case report of a complete response and 20-year survival of a patient with a recurrent diffuse intrinsic brainstem anaplastic astrocytoma. Neuro-Oncology 2007;9:536.

24 Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells. Neuro-Oncology 2007;9:482.

25 Burzynski, S.R. The Genetic Solution for Anti-Aging. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;63-70.

26 Burzynski, S.R. Genetics of Brain Aging (I). Gene Silencing in Neurons. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;71-78.

27 Burzynski, S.R. Genetics of Brain Aging (II). Genetic Mechanisms in Encoding and Consolidation of Memory. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;79-88.

28 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS 2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas. Neuro-Oncology 2007;9:206.

29 Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (5). Genes and aging of the neurons. Geny a starzenie neuronow. Czasopismo Aptekarskie 2007; Nr 3 (159) 27-38.

30 Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (4). Time factor in biology and medicine. Czynnik czasu w biologii i medycynie. Czasopismo Aptekarskie 2007; Nr 2 (158) 27-36.

31 Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (3). The medicine of aging population. Medycyna starzejacego sie spoleczenstwa. Czasopismo Aptekarskie 2007; Nr 1 (157) 39-48.

32 Burzynski, S.R. Targeted Therapy for Brain Tumors. Columbus F, ed. Brain Cancer Therapy and Surgical Interventions. New York (NY); Nova Science Publishers, Inc. 2006;77-111.

33 Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (2). Epigenome and gene silencing. Epigenom i wyciszanie genow. Czasopismo Aptekarskie 2006;Nr 12 (156) 29-36.

34 Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (1). The medicine of genome an epigenome. Medycyna genomu i epigenomu. Czasopismo Aptekarskie 2006;Nr 11 (155) 45-52.

35 Burzynski, S.R. Age Management Treatments Which Target Silenced Genes. Redberry GW, ed. Gene Silencing: New Research. Nova Science Publishers, Inc. 2006.

36 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Khan, M.I., Dolgopolov, V. Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A10 and AS2-1. Neuro-Oncology. 2006;10:466.

37 Burzynski, S.R., Weaver, R.A., Szymkowski, B., Janicki, T.J., Khan, M.I., Dolgopolov, V. Complete response of a diffuse intrinsic brainstem tumor and von Hippel Lindau (VHL) disease to antineoplastons A10 and AS2-1 (ANP): a case report. Neuro-Oncology. 2006;10:439.

38 Burzynski, S.R. Treatments for Astrocytic Tumors in Children: Current and Emerging Strategies. Pediatric Drugs 2006;8:167-178.

39 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma. Integrative Cancer Therapies 2006; 5(1):40-47.

40 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B.G., Jurida, G.F., Burzynski, B. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in patients with recurrent, diffuse intrinsic brain stem gliomas. Neuro-Oncology 2006;10:346.

41 Burzynski, S.R. Master Clock of Life (II). How to Turn the Clock Back. In: American Academy of Anti-Aging Medicine. American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics;Volume VIII 2006.

42 Burzynski, S.R. Master Clock of Life (I). "Junk DNA." and Promoters Regions as Major Components of the Clock. American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics;Volume VIII 2006.

43 Burzynski, S. R. Gene silencing theory of aging: the clinical trial supporting the theory. Anti-Aging Therapeutics 2005;Vol VII:39-46.

44 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas. Neuro-Oncology 2005;7:300.

45 Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP. Neuro-Oncology 2005;7:299.

46 Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 AS2-1. Integrative Cancer Therapies 2005;4(2):168-177.

47 Burzynski, S.R. Aging: Gene silencing or gene activation? Med Hypoth 2005; 64, 201-208.

48 Burzynski, S.R. Mechanizmy i profilaktyka genetycznego starzenia. Mechanisms and prevention of genetic aging. Neurologia I Psychiatria 2004;4:1-8.

49 Burzynski, S.R., Ilkowska-Musial, E., Klimczak M.W., Musial, L. Antineoplastons In Dairy Products. Journal of Applied Nutrition 2004;54;1-8.

50 Burzynski, S.R., Weaver, R. Bestak. M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma. Neuro-Oncology 2004;6:386.

51 Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme. Neuro-Oncology 2004;6:384.

52 Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V. Treatment of primitive neuroectodermal tumors (PNET) with antineoplastons A10 and AS2-1 (ANP). Preliminary results of phase II studies. Neuro-Oncology 2004;6:428.

53 Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system. A preliminary report. Neuro-Oncology 2004;6:427.

54 Burzynski, S.R., Lewy, R.I., Weaver, R., Janicki, T., Jurida, G., Khan, M., Larisma, C.B., Paszkowiak, J., Szymkowski, B. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. Integrative Cancer Therapies 2004;3:257-261.

55 Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Bestak, M. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma. A Preliminary Report. Drugs R&D 2004;5(6):315-326.

56 Burzynski, S.R. The Present State of Antineoplaston Research. Integrative Cancer Therapies 2004;3:47-58.

57 Burzynski, S.R., Lewy, R.I., Weaver, R.A., Axler, M.L., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I., Bestak, M. Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma (Preliminary Report). Drugs in R&D 2003;4:91-101.

58 Waldbillig R, Burzynski SR. Mechanism of action, uptake, and gene array studies on the antineoplastic agent phenylacetylglutamine (PG) in human glioma cells U-87. Neuro-Oncology 2003;10:309.

59 Burzynski, S.R., Weaver, R.A., Bestak, M., Lewy, R.I., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive multicentric glioma. A preliminary report. Neuro-Oncology 2003;10:358.

60 Burzynski, S.R. The Methylation Control of Gene Activation and Silencing Theory. The Basic Principles and Practice of Anti-Aging Medicine & Age Management for the Aesthetic Surgeon and Physician. Vincent C. Giampapa (Ed.) 2003;33-4.

61 Burzynski, S.R., Maxwell L. Axler, Robert I. Lewy, Tomasz Janicki, Elwira Ilkowska-Musial, Anna Baranowska, M.Sc. Amino Acid Supplementation in Treatment of Cancer-Related Symptoms. Journal of Applied Nutrition 2003; 53:52-60.

62 Burzynski, S. R. Gene Silencing - A New Theory of Aging. Med Hypoth 2003; 60:578-583.

63 Burzynski, S.R. Antineoplaston Therapy. Chapter in Integrative Oncology - Conventional and Complementary Strategies. Urban & Fischer; 2002.

64 Burzynski, S.R. Antineoplastons. In: Clinician's Complete Reference To Complementary/Alternative Medicine, Novey, D. W. (Ed.). Mosby 2000;496-507, St.Louis, USA.

65 Burzynski, S.R. The Best of Alternative Medicine. Townsend Letter for Doctors 2000;200:32.

66 Burzynski, S.R., Conde, A.B., Peters, A., Saling B., Ellithorpe, R., Daugherty, J.P., and Nacht C.H. A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumors. Clin. Drug Invest 1999;18:1-10.

67 Burzynski, S.R. Efficacy of Antineoplastons A10 and AS2-1. Mayo Clin. Proc 1999;74:641-643.

68 Burzynski, S.R. Antineoplastons in the treatment of malignant brain tumors. Anti-Aging Medical Terapeutics, vol. 2. Klatz RM., Goldman R. (Ed), Health Quest Publications 1998;28-34, Marina del Rey, Ca, USA.

69 Burzynski, S.R. Antineoplastons, oncogenes and cancer. Anti-Aging Medical Therapeutics, Vol.1. Klatz RM, Goldman R. (Ed), Health Quest Publication 1997; Marina del Rey, CA, USA.

70 Burzynski, S.R. Potential of antineoplastons in diseases of old age. Drugs & Aging 1995;7:157-167.

71 Soltysiak-Pawluczuk, D., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z. Cellular accumulation of antineoplaston AS2-1 in human hepatoma cells. Cancer Letters 88 (1995);88:107-112.

72 Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Mlynarczyk, M., Kleinrok, Z. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Drugs Exptl Clin Res 1995;21:153-156.

73 Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z. The influence of antineoplaston A5 on the central dopaminergic structures. Drugs Exptl Clin Res 1994;20:161-167.

74 Burzynski, S.R. Immunosurveillance versus chemosurveillance. Post Nauk Med 1993;6:260-262.

75 Burzynski, S.R. Antineoplastons, An Investigational Cancer Therapy. Townsend Letter for Doctors 1993;3,150-153.

76 Burzynski, S.R. Novel differentiation inducers. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany.

77 Liau, M.C., Liau, C.P., Burzynski, S.R. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. Internat J Exptl Clin Chemother 1992;5:9-17.

78 Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of drug induced DNA hypermethylation by antineoplaston components. Internat J Exptl Clin Chemother 1992;5:19-27.

79 Lee, S.S., Burzynski, S.R. Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992: Munich, Germany.

80 Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of drug-induced DNA hypermethylation by antineoplastons. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany.

81 Burzynski, S.R, Kubove, E., Burzynski, B. Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany.

82 Lee, S.S., Burzynski, S.R. Antineoplaston A5: A growth inhibitor for cancerous cells and growth stimulator for normal cells. Internat J Exptl Clin Chemother 1991;4:63-65.

83 Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Protective effect of antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1. Internat J Tissue Reactions 1990;12 (suppl):43-50.

84 Liau, M.C., Lee, S.S., Burzynski, S.R. Modulation of cancer methylation complex isoenzymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5. Internat J Tissue Reactions 1990; 12 (suppl): 27-36.

85 Lee, S.S., Burzynski, S.R. Inducibility of HL-60 leukemic cells to undergo terminal differentiation after repeated treatment with antineoplaston A5. Internat J Exptl Clin Chemother 1990;3:125-128.

86 Lee, S.S., Burzynski, S.R. Induction of differentiation of HL-60 human promyelocytic leukemic cell by antineoplaston A5. Internat J Tissue Reactions 1990;12(suppl):37-42.

87 Liau, M.C., Ashraf, A.Q., Lee, S.S., Hendry, L.B., Burzynski, S.R. Riboflavin as a minor active anticancer component of antineoplaston A2 and A5. Internat J Tissue Reactions 1990;12:19-26.

88 Liau, M.C., Lee, S.S., Burzynski, S.R. Separation of active anticancer components of antineoplaston A2, A3, and A5. Internat J Tissue Reactions 1990; 12 (suppl): 1-17.

89 Burzynski, S.R., Kubove, E., Burzynski, B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exptl Clin Res 1990;16: 361-369.

90 Burzynski, S.R. Isolation, purification and synthesis of antineoplastons. Internat J Exptl Clin Chemother 1989;2:63-69.

91 Liau, M.C., Lee, S.S., Burzynski, S.R. Hypomethylation of nucleic acids: A key to the induction of terminal differentiation. Internat J Exptl Clin Chemother 1989;2:187-199.

92 Hendry, L.B., Muldoon, T.G., Burzynski, S.R. Modeling studies suggest the modified dipeptide analog phenylacetylamino-2, 6-piperidinedione may interact with DNA. Adv Exptl Clin Chemother. 1988; 2: 11-13.

93 Burzynski, S.R. Antineoplastons: Basic research and clinical applications. Adv Exptl Clin Chemother. 1988; 2: 1-9.

94 Burzynski, S.R. Isolation, purification and synthesis of antineoplastons. Adv Exptl Clin Chemother. 1988; 6: 1-7.

95 Liau, M.C., Lee, S.S, Burzynski, S.R. Differentiation inducing components of antineoplaston A5. Adv Exptl Clin Chemother. 1988; 6: 9-25.

96 Lee, S.S., Burzynski, S.R. Terminal differentiation of HL-60 human promyelocytic leukemia cells induced by antineoplaston A2. Adv Exptl Clin Chemother 1988;6:27-31.

97 Burzynski, S.R. Treatment of bladder cancer with antineoplaston formulations. Adv Exptl Clin Chemother. 1988. 2: 37-46.

98 Burzynski, S.R., Kubove, E., Burzynski, B. Phase I clinical studies of oral formulation of antineoplaston AS2-1. Adv Exptl Clin Chemother 1988;2:29-36.

99 Burzynski, S.R. Treatment of malignant brain tumors with antineoplastons. Adv Exptl Clin Chemother 1988;6:45-56.

100 Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats. Adv Exptl Clin Chemother 1988;6:33-39.

101 Ashraf, A.Q., Burzynski, S.R. Comparative study of antineoplaston A10 levels in plasma of healthy people and cancer patients. Adv Exptl Clin Chemother 1988;2: 19-28.

102 Lee, S.S., Burzynski, S.R. Tissue culture and animal toxicity studies of antineoplaston A5. Drugs Exptl Clin Res 1987;13 (suppl 1):31-35.

103 Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Chemoprevention by antineoplaston A10 of benzo (a) pyrene-induced pulmonary neoplasia. Drugs Exptl Clin Res 1987;13 (suppl 1):51-55.

104 Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Chemosurveillance: A novel concept of the natural defense mechanism against cancer. Drugs Exptl Clin Res 1987;13 (suppl 1):71-76.

105 Lee, S.S., Mohabbat, M.O., Burzynski, S.R. In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3. Drugs Exptl Clin Res 1987;13 (suppl 1):13-16.

106 Khalid, M., Burzynski, S.R. N,N'-disubstituted L-isoglutamines as novel cancer chemotherapeutic agents. Drugs Exptl Clin Res 1987;13 (suppl 1):57-60.

107 Hendry, L.B., Muldoon, T.G., Burzynski, S.R., Copland, J.A., Lehner, A.F. Stereochemical modeling studies of the interaction of antineoplaston A10 with DNA. Drugs Exptl Clin Res 1987;13 (suppl 1):77-81.

108 Burzynski, S.R., Kubove, E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years follow-up. Drugs Exptl Clin Res 1987;13 (suppl 1):1-12.

109 Burzynski, S.R., Kubove, E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exptl Clin Res 1987;13 (suppl 1):17-29.

110 Burzynski, S.R., Kubove, E., Burzynski, B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exptl. Clin Res 1987;13 (suppl 1):37-43.

111 Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs Exptl Clin Res 1987;13 (suppl 1):61-70.

112 Ashraf, A.Q., Liau, M.C., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats. Drugs Exptl Clin Res 1987;13 (suppl 1):45-50.

113 Burzynski, S.R., Mohabbat. M.O. Chronic animal toxicity studies of antineoplaston A2. Drugs Exptl Clin Res 1986;12 (suppl 1):73-75.

114 Ashraf, A.Q., Liau, M.C., Mohabbat, M.O., Burzynski, S.R. Preclinical studies of antineoplaston A10 injections. Drugs Exptl Clin Res 1986;12 (suppl 1):37-45.

115 Burzynski, S.R., Mohabbat, M.O., Lee, S.S. Preclinical studies of antineoplaston AS2-1 and antineoplaston AS2-5. Drugs Exptl Clin Res 1986;12 (suppl 1):11-16.

116 Burzynski, S.R. Antineoplaston A3. Drugs of the Future 1986;11:551-552.

117 Burzynski, S.R. Antineoplastons - History of the research (I). Drugs Exptl Clin Res 1986;12 (suppl 1):1-9.

118 Burzynski, S.R. Antineoplaston AS2-5. Annual Drug Data Report 1986;8:319.

119 Burzynski, S.R. Antineoplaston AS2-1. Annual Drug Data Report 1986;8:320.

120 Burzynski, S.R., Khalid, M. Antineoplaston AS2-5. Drugs of the Future 1986;11:364-365.

121 Burzynski, S.R. Antineoplaston A10 injections. Annual Drug Data Report 1986;8:597.

122 Burzynski, S.R. Antineoplaston A3. Annual Drug Data Report 1986;8:412.

123 Burzynski, S.R. Antineoplaston A2. Annual Drug Data Report 1986;8:504.

124 Burzynski, S.R., Khalid, M. Antineoplaston AS2-1. Drugs of the Future 1986; 11: 361-363.

125 Burzynski, S.R. Antineoplaston A2. Drugs of the Future 1986;11:549-550.

126 Burzynski, S.R. Antineoplaston A5. Annual Drug Data Report 1986;8:869.

127 Burzynski, S.R. Antineoplaston A5. Drugs of the Future 1986;11:824-825.

128 Burzynski, S.R. Synthetic antineoplastons and analogs. Drugs of the Future 1986;11: 679-688.

129 Liau, M.C., Burzynski, S.R. Altered methylation complex isoenzymes as selective targets for cancer chemotherapy. Drugs Exptl Clin Res 1986;12 (suppl 1):77-86.

130 Lehner, A.F., Burzynski, S.R., Hendry, L.B. 3-phenylacetylamino-2, 6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA. Drugs Exptl Clin Res 1986;12 (suppl 1):57-72.

131 Burzynski, S.R., Kubove, E. Toxicology studies of antineoplaston A10 injections in cancer patients. Drugs Exptl Clin Res 1986;12 (suppl 1):47-55.

132 Burzynski, S.R. Toxicology studies of antineoplaston AS2-5 injections in cancer patients. Drugs Exptl Clin Res 1986;12 (suppl 1):17-24.

133 Burzynski, S.R., Burzynski, B., Mohabbat, M.O. Toxicology studies of antineoplaston AS2-1 injections in cancer patients. Drugs Exptl Clin Res 1986;12 (suppl 1):25-35.

134 Lee, S.S., Mohabbat, M.O., Burzynski, S.R. Tissue culture and acute animal toxicity studies of antineoplaston A2. Future Trends in Chemotherapy 1985;6:481-484.

135 Burzynski, S.R., Hai TT. Antineoplaston A10. Drugs of the Future 1985;10:103-105.

136 Burzynski, S.R. Phase I clinical studies of antineoplaston AS2-5 injections. Recent Advances in Chemotherapy. Ishigami J. (Ed), University of Tokyo Press. 1985; Tokyo, Japan.

137 Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology studies on oral formulation of antineoplaston A10 in cancer patients. Future Trends in Chemotherapy 1985;6:485-493.

138 Burzynski, S.R., Mohabbat MO, Burzynski B. Animal toxicology studies on oral formulation of antineoplaston A10. Drugs Exptl Clin Res 1984;10:113-118.

139 Lee, S.S., Mohabbat, M.O., Burzynski, S.R. Tissue culture and animal toxicity studies of antineoplaston A2. Drugs Exptl Clin Res 1984;10:607-610.

140 Burzynski, S.R. Antineoplaston A10. Annual Drug Data Report 1984;6:124.

141 Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Human toxicology studies on oral formulation of antineoplaston A10. Drugs Exptl Clin Res 1984;10:891-909.

142 Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology studies on oral formulation of antineoplaston A10 in cancer patients. Drugs Exptl Clin Res 1984;10:611-619.

143 Beall, P., Szopa, B., Burzynski, S.R., Hazlewood, C.F. Polypeptides that inhibit human breast cancer cell division. Cancer Biochem Biophys 1979;3:93-96.

144 Burzynski, S.R. Antyneoplastony. Przeglad Lekarski 1978;6:583-586.

145 Gross S, Galicka N, Grabarczyk M, Giannini M, Burzynski SR, Stolzmann Z. Urinary peptides inhibit DNA synthesis in vitro in certain cultured neoplastic cells. Clin Chem 1977;23:148-149.

146 Burzynski, S.R., Stolzmann, Z., Szopa, B., Stolzmann, E., Kaltenberg, O.P. Antineoplaston A in cancer therapy (I). Physiol Chem Phys 1977;9:485-500.

147 Burzynski, S.R. Antineoplastons: Biochemical defense against cancer. Physiol Chem Phys 1976;8:275-279.

148 Gross, S., Galicka, N., Burzynski, S.R., Stolzmann, A. Urinary peptides in muscular dystrophy. Physiol Chem Phys 1976;8:161-166.

149 Burzynski, S.R. Sequential analysis in subnanomolar amounts of peptides; Determination of the structure of a habituation-induced brain peptide (ameletin). Anal Biochem 1976;70:359-365.

150 Burzynski, S.R., Loo, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H. Biologically active peptides in human urine: III. Inhibitors of the growth of leukemia, osteosarcoma and HeLa cells. Physiol Chem Phys 1976;8:13-22.

151 Burzynski, S.R., Rao, P.N., Gross, S., Stolzman, Z. Inhibition of the Growth of HeLa Cells by the Peptide Isolated from Normal Human Urine. Fed Proc 1976;35:623.

152 Burzynski. S.R. Quantitative analysis of amino acids and peptides in the femtomolar range. Anal Biochem 1975;65:93-99.

153 Burzynski, S.R., Ungar, G. Brain Peptides Associated with Habituation to a Sound Stimulus. Neuroscience Abstracts 1975;1:329.

154 Ungar, G., Burzynski, S.R., Tate, D.L. Learning-induced Brain Peptides. Peptides: Chemistry, structure and biology. Walter, R., Meienhofer, J. (Ed), Ann Arbor Science; 1975; Ann Arbor, Michigan, USA.

155 Burzynski, S.R., Ungar, A.L., Lubanski, E. Biologically active peptides in human urine: II. Effect on intestinal smooth muscle and heart. Physiol Chem Phys 1974;6:457-468.

156 Burzynski, S.R., Ungar, A.L., Lubanski, E. Effect of Urinary Peptides on Smooth Muscle and Heart. Fed Proc 1974;33:547.

157 Burzynski, S.R. Biologically active peptides in human urine: I. Isolation of a group of medium-sized peptides. Physiol Chem Phys 1973;5:437-447.

158 Burzynski, S.R., Georgiades, J. Effect of Urinary Peptides on DNA, RNA and Protein Synthesis in Normal and Neoplastic Cells. Fed Proc 1973;32:766.

159 Ungar, G., Burzynski, S.R. Isolation and Purification of a Habituation-inducing Peptide from Trained Rat Brain. Fed Proc 1973;32:367.

160 Burzynski, S., Czerniak, Z. A simple method for the separation of free and bound amino acids and its application to the identification of bound amino acids in human blood serum. Chem Anal 1970;15:223-225.

161 Szajner-Milart, J., Burzynski, S.R., Paczos-Chadyma, E., Czerniak, Z. Free amino acids in serum of obese children. Endokr Pol 1970;21:611-617.

162 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of carbohydrates and their statistical analysis, I. Results obtained in various conditions using paper and thin-layer chromatography. Chem Anal 1969;13:1221-1228.

163 Burzynski, S. Investigations on unknown ninhydrin-reacting substances in human blood serum I. Attempts at identification of three such substances. Experientia 1969;25:490-491.

164 Burzynski, S. Bound amino acids in serum of patients with chronic renal insufficiency. Clin Chim Acta 1969;25:231-237.

165 Czerniak, Z., Burzynski, S. Free amino acids in serum of patients with chronic renal insufficiency. Clin Chim Acta 1969;24:367-372.

166 Burzynski, S., Czerniak, Z. A simple method for free and bound amino acid separation. Folia Soc Sci Lub 1969/70;Sec. A-D 9/10 (suppl):143-144.

167 Burzynski, S., Czerniak, Z. Quantitative determination of amino acids using photometry of negative printed chromatograms. Modification of the method and its application for amino acid analysis in blood serum. Chem Anal 1969;14:667-671.

168 Czerniak, Z., Burzynski, S. Qualitative analysis of amino acids using the multiple development of chromatograms in different eluents. Chem Anal 1969;14:673-676.

169 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of free amino acids in human blood with the use of our own method and Beckman amino acid analyzer. Pol Arch Med Wewn 1968;40:223-228.

170 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of free amino acids in the blood of patients with myocardial infarction using a new method of photometry of the negative printed chromatograms. Pol Arch Med Wewn 1968;41:361-368.

171 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of carbohydrates and their statistical analysis, II. Analysis of variance for four-crossed classification and Tukey confidence intervals. Chem Anal 1968;13:1229-1238.

172 Burzynski, S. Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency. 1968; Lublin, Poland: 274 pp (doctoral dissertation).

173 Krzeczkowska, I., Burzynski, S. Czerniak Z. Quantitative determination of amino acids using photometry of negative printed chromatograms. Ann Univ MC Sklodowska 1966;21:125-134.

174 Krzeczkowska, I., Czerniak, Z., Burzynski, S. The application of the negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people. Ann Univ MC Sklodowska 1966;21:313-322.

175 Krzeczkowska, I., Burzynski, S., Czerniak, Z. Investigations on the possibility of the determination of mushroom species on the basis of the composition of their amino acids. Ann Univ MC Sklodowska 1965;20:221-229.

176 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Free and bound amino acids of some edible mushrooms. Ann Univ MC Sklodowska 1965;20:303-312.

177 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Bound amino acids of some edible mushrooms. Ann Univ MC Sklodowska 1964;19:329-336.

178 Krzeczkowska, I., Burzynski, S., Czerniak, Z. Free amino acids of some edible mushrooms. Ann Univ MC Sklodowska 1964;19:321-328.

SELECTED ABSTRACTS OF PRESENTATIONS BY S.R. BURZYNSKI AND ASSOCIATES

1 Burzynski, S.R. Molecular profiling in oncology practice: The results of treatment in a group of 1,633 patients." Presented at BIT's 4th Annual World Cancer Congress – 2011; May 22-25, 2011; Dalian, China.

2 Burzynski, S.R, Weaver, R.A., Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S. OT-15. Preliminary results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas. Presented at the 15th Annual Scientific Meeting of the Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada.

3 Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. CB-15. Targeting microRNAs in glioma cells with antineoplastons. Presented at the 15th Annual Scientific Meeting of the Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada.

4 Burzynski, S.R, Weaver, R.A., Janicki, T., E, Szymkowski, B., Acelar, S.S., Burzynski, G.S. A phase II study of antineoplaston A10 and AS2-1 injections in children with low-grade astrocytomas. Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna, Austria.

5 Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells. Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna, Austria.

6 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S. Phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Protocol BC-BT-11. Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

7 Weaver, R.A., Szymkowski, B., Burzynski, S.R. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP). Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

8 Patil, S., Burzynski, S.R., Chittur, S., Mrowczynski, E., Grela, K. Antineoplastons inhibit MCM complex in glioblastoma cells. Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

9 Burzynski, S.R. New research on molecular mechanisms and prevention of Alzheimer's disease. Presented at the 17th Annual world Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies, Spring 2009 Session; April 21-April 25, 2009; Orlando, Florida.

10 Burzynski, S. Life extension through application of chromatin remodeling agents. Presented at the 7th Anti-Aging Medicine World Congress & Medispa; March 19-March 21, 2009; Monte-Carlo, Monaco.

11 Marquis, A., Kubove, E., Walczak, M., Burzynski, S. Hepatocellular carcinoma, recurrent after standard therapy, successfully treated with a combination of targeted therapies. Presented at the 20th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France.

12 Weaver, R., De Leon, L., Burzynski, S. A complete response in a patient with inoperable adenocarcinoma of the head of the pancreas treated with a combination of gene-targeted therapies. Presented at the 20th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France.

13 Burzynski, S.R. The Coming Pandemic of Liver Cancer. In Search of Genomic Solutions. Presented at the 16th Annual World Congress of A4M, Winter 2008 Session; December 12-December 15, 2008; Las Vegas, Nevada.

14 Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Samuel, S., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report. Presented at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology; November 20-November 23, 2008; Las Vegas, Nevada.

15 Burzynski, S.R., Patil, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints leading to apoptosis in human glioblastoma cells. Presented at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology; November 20-November 23, 2008; Las Vegas, Nevada.

16 Burzynski, S.R., Patil, S., Ilkowska-Musial, E., Chittur, S., Gupta, V., Sarangi, R. Pathway analysis of the effect of chromatin remodeling agent phenylbutyrate on the brains of honeybees. Presented at Neuroscience 2008; November 15-November 19, 2008; Washington D.C.

17 Burzynski, S.R. Practical Application of Gene Silencing Theory of Aging. Life Extension in Animals and Human Clinical Trials. Presented at the Dubai Congress on Anti-Aging and Aesthetic Medicine (DCAAAM); November 7-November 9, 2008; Dubai.

18 Burzynski, S.R. Antineoplastons and Targeted Gene Therapy. Presented at ACAM Scientific Conference; October 15-October 19, 2008; Las Vegas, Nevada.

19 Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Walczak, M., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma. Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain.

20 Patil, S., Burzynski, S.R., Chittur, E., Mrowczynski, K.G. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells. Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain.

21 Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animal testing and human clinical trials. Presented at the European Congress on Anti-Aging & Aesthetic Medicine (ECAAAM); September 11-September 14, 2008; Düsseldorf, Germany.

22 Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S. Phase II study of antineoplastons A10 and AS2-1 (ANP) in children with optic pathway glioma: A preliminary report. Presented at the 13th International Symposium on Pediatric Neuro-Oncology; June 29-July 2, 2008; Chicago, Illinois.

23 Burzynski, S.R. Genome, Epigenome and Aging. Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal.

24 Burzynski, S.R. Personalized Cancer Treatment in Genomics Era. Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal.

25 Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animals and human clinical trials. Presented at the 16th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; April 25-27, 2008; Orlando, Florida.

26 Burzynski, S.R. Antineoplaston peptides in treating cancer. Presented at the 2008 Orthomolecular Health-Medicine conference; February 29-March 2, 2008; San Francisco, California.

27 Burzynski, S.R. Anti-Aging peptides—a new frontier in healing. Presented at the 2008 Orthomolecular Health-Medicine conference; February 29-March 2, 2008; San Francisco, California.

28 Burzynski, S.R. Genomic approach to cancer treatment. Presented at the 15th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; December 12-15, 2007; Las Vegas, Nevada.

29 Burzynski, S.R. Genomics in Cancer Treatment. Presented at the 1st Annual India Conference on Anti-Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India.

30 Burzynski, S.R. Epigenomic Approach to Anti-Aging. Presented at the 1st Annual India Conference on Anti-Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India.

31 Burzynski, S.R., Weaver, R.A., Szymkowski, B. A case report of a complete response and 20-year survival of a patient with a recurrent, diffuse, intrinsic brainstem anaplastic astrocytoma. Presented at the Society for Neuro-Oncology 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas.

32 Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells. Presented at the Society for Neuro-Oncology 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas.

33 Burzynski, S.R., Tempczyk-Russell, A., Ilkowska-Musial, E. Amyloid precursor protein (APP) and related protein fragmentation in consolidation of memory. Presented at Neuroscience 2007, the Society's Annual Meeting; November 3-7, 2007; Sand Diego, California.

34 Burzynski, S.R. Epigenomic approach to anti-aging. Presented at: 4th Congresso Internacional de Antienvelhecimento; October 26-27, 2007; Sao Paulo, Brazil.

35 Burzynski, S.R. Nutrition and ageing : Gene silencing or gene activation. Presented at: 10th European Nutrition Conference; July 10-13, 2007; Paris, France.

36 Burzynski, S.R. La solution génétique contre le vieillissement. Presented at: Anti-Aging Medicine World Congress; March 22-24, 2007; Monte Carlo.

37 Burzynski, S.R. Genetics of Brain Aging (II). Genetic Mechanisms in Encoding and Consolidation of Memory. Presented at: 14th Annual International Congress on Anti-Aging Medicine; December 7-10, 2006; Las Vegas, Nevada.

38 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.J., Khan, M.I., Dolgopolov, V. Treatment of multicentric brainstem gliomas with Antineoplastons (ANP) A10 and AS2-1. Presented at the Society for Neuro-Oncology's 11th Annual Meeting; November 16-19, 2006; Orlando, Florida.

39 Burzynski, S.R., Christensen, R., Ilkowska-Musial, E. Memory processing proteins have common amino acid sequences with Scotophobin. Presented at: Neuroscience 2006, the Society's 36th annual meeting; October 14-18, 2006; Atlanta, Georgia.

40 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B., Jurida, G.F. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in adult patients with diffuse intrinsic brainstem gliomas. Presented at: The European Association for Neuro Oncology: 7th Congress Vienna Hofburg Congress Center; September 14-17, 2006; Vienna, Austria.

41 Burzynski, S.R. Genetics of Brain Aging (I). Gene Silencing in Neurons. Presented at: 14th Annual International Congress on Anti-Aging Medicine; July 14-16, 2006; Chicago, Illinois.

42 Burzynski, S.R. The Genetic Solution for Anti-Aging. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

43 Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (III) Aminocare Products and Aging of the Brain. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

44 Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (II) Aminocare Products and Skin Aging. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

45 Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (I) Theory and Age-Management with Aminocare Products. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan

46 Burzynski, S.R. Gene Silencing Theory of Aging. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

47 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas. Presented at: 12th International Symposium on Pediatric Neuro-Oncology; June 6-9, 2006; Nara, Japan.

48 Burzynski, S.R. Chronobiology of Aging. Presented at: International Danube Symposium for Neurological Sciences and Continuing Education; May 10-13, 2006; Kazimierz Dolny, Poland.

49 Burzynski, S.R. The Genetic Solution for Anti-Aging. Presented at: 14th International Congress on Anti-Aging Medicine; April 7-9, 2006; Orlando, Florida.

50 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Jurida, G.F. Burzynski, B. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in patients with recurrent, diffuse intrinsic brain stem gliomas. Presented at the 17th International Congress on Anti-Cancer Treatment; January 30-February 2, 2006; Paris, France.

51 Burzynski, S.R. Master Clock of Life (II). How to Turn the Clock Back. Presented at: XIII International Congres on Anti-Aging Medicine; December 8-12, 2005; Las Vegas, Nevada.

52 Burzynski, S.R. Master Clock of Life (I) "Junk DNA" and Promotors Region as Major Components of the Clock. Presented at: XIII International Congres of Anti-Aging Medicine; August 19-21, 2005; Chicago, Illinois.

53 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas. Presented at: 2nd Quadrennial meeting of the World Federation of Neuro-Oncology/ 6th meeting of the European Association of NeuroOncology; May 5-8, 2005; Edinburgh, Scotland, UK.

54 Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP. Presented at: 2nd Quadrennial meeting of the World Federation of Neuro-Oncology/ 6th meeting of the European Association of NeuroOncology; May 5-8, 2005; Edinburgh, Scotland, UK.

55 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 (ANP) of high grade, recurrent and progressive brain stem glioma. Presented at the 16th International Congress on Anti-Cancer Treatment; February 1-4, 2005; Paris, France.

56 Burzynski, S.R. Antineoplastons. Presented at: The Cleveland Clinic Neuro-Oncology 2005: Current Concepts; January 29-31, 2005; Lake Buena Vista, FL, USA.

57 Burzynski, S.R., Jacquet, A., Moore, N., Musial, L. Gene silencing theory of aging: the clinical trial supporting the theory. Presented at: American Academy of Anti-Aging Medicine (A4M) Conference on Anti-Aging Medicine, December 2-5, 2004; Las Vegas, USA.

58 Burzynski, S.R., Weaver, R. Bestak. M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma. Presented at: 9th Annual Meeting Society for Neuro-Oncology, November 18-21, 2004; Toronto, Canada.

59 Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme. Presented at: 9th Annual Meeting Society for Neuro-Oncology, November 18-21, 2004; Toronto, Canada.

60 Burzynski, S.R., Janicki, T., Weaver, R., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Clinical application of body epigenetic system. Multi-targeted therapy for primary brain tumors. Presented at World Conference on Magic Bullets Celebrating Paul Ehrlich's 150th Birthday; September, 2004; Nurnberg, Germany.

61 Burzynski, S.R. The new generation of food supplements effecting gene expression. Presented at 2nd Congress Food, Nutrition and Health in Poland Intergrated with European Union; June 23-26, 2004; Warsaw, Poland.

62 Burzynski, S.R., Weaver, R.A., Bestak, M., Janicki, T.J, Szymkowski, B., Jurida G., Khan, M., Dolgopolov, V. Treatment of Primitive Neuroectodermal Tumors (PNET) with Antineoplastons A10 and AS2-1 (ANP). Preliminary Results of Phase II Studies. Presented at 11th International Symposium on Pediatric Nuero-Oncology; June 13-16, 2004; Boston, MA.

63 Burzynski, S.R., Weaver, R.A., Bestak, M., Janicki, T.J, Jurida G., Szymkowski, B., Khan, M., Dolgopolov, V. Phase II Studies of Antineoplastons A10 and AS2-1 (ANP) in Children with Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System. A Preliminary Report. Presented at 11th International Symposium on Pediatric Neuro-Oncology; June 13-16, 2004; Boston, MA.

64 Burzynski, S.R., Lewy, R.I., Axler, M., Janicki, T.J. Treatment of Malignant Mesothelioma (MM) with Sodium Phenylbutyrate. Presented at the 15th International Congress on Anti-Cancer Treatment; February 9-12, 2004, Paris, France.

65 Waldbillig, R.J., Mrowczynski, E., Burzynski, S.R. Phenylacetic acid (PN) and Phenylacetylglutamine (PG): Mechanism of Uptake and changes in Epigenetic-Mechanisms Regulating Gene Expression. Presented at the 2nd Annual American Association for Cancer Research (AACR) International Conference; October 26-30, 2003, Phoenix, AZ.

66 Burzynski, S.R. Interaction of antineoplastons with genome in cancer and aging. Presented at: Annual Meeting of International Academy of Oral Medicine and Toxicology; September 12-13, 2003, New Orleans, Louisiana.

67 Burzynski, S.R. Antineoplastons in: Cancer Treatment and Age Management Therapy. Presented at American Collage for Advancement in Medicine (ACAM); May 16, 2003, Washington, DC.

68 Burzynski, S.R. The State of Antineoplaston Research - Spring of 2003. Presented at the 5th Annual Comprehensive Cancer Care Conference; April 11, 2003, Washington, DC.

69 Waldbillig, R.J., Burzynski, S.R. The application of chromatography to the pharmacokinetic study of Antineoplastons A10 and AS2-1. Presented at the 3rd International Symposium of Chromatography and Natural Products; June 12-15, 2002, Lublin, Poland.

70 Burzynski, S.R. Antineoplastons. Presented at 'Health-Trends 2000', The 2nd International Conference; August 27-29, 1999, Copenhagen, Denmark.

71 Burzynski, S.R. Phase II Trial of Antineoplaston A10 and AS2-1 in Brain Stem Glioma. Presented at International Conference on Integrative Medicine; May 1, 1999, Seattle, Washington, USA.

72 Czerwinski, A., Klimczak, M.W., Burzynski, S.R. Enancjoselektywna analiza skladnikow Antyneoplastonu A10 metoda HPLC. Presented at the XVII Naukowy Zjazd Polskiego Towarzystwa Farmaceutycznego, September 1998, Krakow, Poland.

73 Burzynski, S.R. Gene Therapy with Antineoplastons. Presented at Comprehensive Cancer Care; June, 1998, Washington, D.C., USA.

74 Burzynski, S.R. Antineoplastons in the Treatment of Malignant Brain Tumors. Presented at 5th International Conference of Anti-Aging Medicine and Biomedical Technology; December, 1997, Las Vegas, Nevada, USA.

75 Burzynski, S.R. New Concepts in Innovative Cancer Therapies. Presented at 4th Annual Conference on Anti-Aging Medicine and Biomedical Technology; Dec., 1996, Las Vegas, Nevada, USA.

76 Burzynski, S.R. Antineoplastons Today. Presented at the First International Congress On Alternative & Complementary Medicine; May, 1995; Washington, DC, USA.

77 Soltysiak-Pawluczuk, D., Burzynski, S.R. Uptake Characteristics of Antineoplaston AS2-1 by Human Hepatoma Cells. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

78 Lee, S.S., Burzynski, S.R. Synergistic Inhibitory Effect of Antineoplaston A5 and Thymidine on the Growth of Human Cancer Cell Lines. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

79 Liau, M.C., Liau, C.P., Burzynski, S.R. Helper Inducers of Terminal Differentiation. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

80 Burzynski, S.R., Szymkowski, B., Kubove, E. Phase II Clinical Trials of Antineoplaston AS2-1 in Asymptomatic HIV Infection. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

81 Burzynski, S.R., Kubove, E., Szymkowski, B. Phase II Clinical Trials of Antineoplaston A10 and AS2-1 Infusions in High Grade Glioma. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

82 Kleinrok, Z., Burzynski, S.R., Juszkiewicz, M., Chodkowska, A., Feldo, M. The Influence of Antineoplaston A5 on the Central Dopaminergic Structures. Presented at: 11th Congress of the Polish Pharmacological Society; September, 1992; Gdansk, Poland.

83 Burzynski, S.R., Kubove, E., Szymkowski, B., Burzynski, B. Phase II Clinical Trials of Novel Differentiation Inducer - Antineoplaston AS2-1 in AIDS and Asymptomatic HIV Infection. VIII International Conference on AIDS/III STD World Congress; July, 1992; Amsterdam, The Netherlands.

84 Burzynski, S.R. Differentiation Inducers-Possible Agents for Cancer Therapy in Pregnancy. Presented at the World Congress of Prenatal and Perinatal Psychology and Medicine; May, 1992; Krakow, Poland.

85 Burzynski, S.R., Kubove, E., Burzynski, B. Phase II Clinical Trials of Antineoplaston A10 and AS2-1 Infusions in Astrocytoma. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.

86 Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of Drug-Induced DNA Hypermethylation by Antineoplastons. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.

87 Lee, S.S., Burzynski, S.R. Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.

88 Liau, M.C., Lee, S.S., Liau, C.P., Burzynski, S.R. Efficient Methylation when Locked in Place Becomes a Major Problem of Cancer. Presented at the 82nd Annual Meeting of the American Association for Cancer Research, May, 1991, Houston, Texas, USA.

89 Burzynski, S.R. Antineoplastons. Presented at: The World Research Foundation Congress, October 7, 1990, Los Angeles, CA, USA.

90 Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic Study of Radioactive Antineoplaston AS2-1 Following Oral Administration in Rats. Presented at the 9th International Symposium on Future Trends in Chemotherapy, March, 1990, Geneva, Switzerland.

91 Burzynski, S.R., Kubove, E., Burzynski, B. Treatment of Hormonally Refractory Cancer of the Prostate with Antineoplaston AS2-1. Presented at the 9th International Symposium on Future Trends in Chemotherapy, March, 1990, Geneva, Switzerland.

92 Liau, M.C., Lee, S.S., Burzynski, S.R. Abnormal Methylation Enzymes as Selective Targets of Cancer Therapy. Presented at the 42nd Annual Symposium on Fundamental Cancer Research, M.D. Anderson Hospital and Tumor Institute; October, 1989; Houston, Texas, USA.

93 Liau, M.C., Lee, S.S., Burzynski, S.R. Hypomethylation of Nucleic Acids: A Key to the Induction of Terminal Differentiation. Presented at the 10th Congress of the Polish Pharmacological Society, September, 1989, Bialystok, Poland.

94 Burzynski, S.R. Antineoplastons - New Way for Cancer Chemotherapy. Presented at the 10th Congress of the Polish Pharmacological Society, September, 1989, Bialystok, Poland.

95 Liau, M.C., Lee, S.S., Burzynski, S.R. Role of Methylation Enzymes in Directing Phenotypic Changes. Presented at the 41st Annual Symposium on Fundamental Cancer Research. M.D. Anderson Hospital and Tumor Institute; October, 1988; Houston, Texas, USA.

96 Liau, M.C., Khalid, M., Burzynski, S.R. Differentiation Inducing Factors of Antineoplaston A5. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

97 Khalid, M., Burzynski, S.R. Phenylacetylglutamine Derivatives as Novel Chemotherapeutic Agents. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

98 Lee, S. S., Burzynski, S.R. Terminal Differentiation of HL-60 Human Promyelocytic Leukemia Cells Induced by Antineoplaston A2. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

99 Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic Analysis of Antineoplaston A10 Injections Following Intravenous Administration in Rats. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

100 Burzynski, S.R. Treatment of Malignant Brain Tumors with Antineoplastons. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

101 Liau, M.C., Lee, S.S., Burzynski, S.R. Modulation of Tumor Methylation Complex Isozymes as a Decisive Factor in the Induction of Differentiation by Antineoplaston A5. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

102 Lee, S.S., Burzynski, S.R. Induction of Differentiation of HL-60 Human Promyelocytic Leukemic Cells by Antineoplaston A5. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

103 Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Protective Effect of Antineoplaston A10 in Hepatocarcinogenesis Induced by Aflatoxin B 1. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

104 Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Oral Formulation of Antineoplaston A3. Presented at the 10th International Congress of Pharmacology, August, 1987, Sydney, Australia.

105 Liau, M.C., Ashraf, A.Q., Burzynski, S.R. Active Anticancer Components of Antineoplaston Formulations. Presented at the 10th International Congress of Pharmacology, August, 1987, Sydney, Australia.

106 Ashraf, A.Q., Burzynski, S.R. Comparative Study of Antineoplaston A10 Levels in Plasma of Healthy People and Cancer Patients. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

107 Burzynski, S.R. Treatment of Bladder Cancer with Antineoplaston Formulations. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

108 Burzynski, S.R. Antineoplastons: Basic Research and Clinical Applications. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

109 Burzynski, S.R. Modeling Studies Suggest the Modified Dipeptide Analog Phenylacetylamino-2, 6-piperidinedione May Interact with DNA. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

110 Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Oral Formulation of Antineoplaston AS2-1. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

111 Lee, S.S., Burzynski, S.R. A Unique Pattern of Growth Inhibition by Antineoplaston A5 on a T-Leukemia Cell Line. Presented at the 14th Annual meeting of the International Society of Oncodevelopmental Biology and Medicine; August, 1986; Helsinki, Finland.

112 Liau, M.C., Kampalath, B.N., Szopa, M., Burzynski, B., Burzynski, S.R. Chemo-surveillance: A Novel Concept on the Natural Defense Mechanism Against Cancer. Presented at the 14th Annual meeting of the International Society of Oncodevelopmental Biology and Medicine; August, 1986; Helsinki, Finland.

113 Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Chemoprevention by Antineoplaston A10 on Benzo (1) pyrene Induced Pulmonary Neoplasia. Presented at the 5th Mediterranean Congress of Chemotherapy; October, 1986; Cairo, Egypt.

114 Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A2 Injections. Presented at the 14th International Cancer Congress; August, 1986; Budapest, Hungary.

115 Hendry, L.B., Lehner, A.F., Muldoon, T.G., Copland, J.A., Mahesh, V.B., Mills, T.M., Burzynski, S.R. Investigations of the Mode of Action of Antineoplaston A10: Evidence for Binding to DNA. Presented at the 14th International Cancer Congress; August, 1986; Budapest, Hungary.

116 Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Antineoplaston A5 Injections. Presented at the III World Conference on Clinical Pharmacology and Therapeutics; July, 1986; Stockholm, Sweden.

117 Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A3 Injections. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

118 Khalid, M., Burzynski, S.R. N,N'-disubstituted L-isoglutamines as Novel Cancer Chemotherapeutic Agents. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

119 Lee, S.S., Mohabbat, M.O., Burzynski, S.R. In Vitro Cancer Growth Iinhibition and Acute Animal Toxicity Studies of Antineoplaston A3. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

120 Lehner, A.F., Copland, J.A., Muldoon, T.G., Burzynski, S.R., Hendry, L.B. In Vitro Studies of the Stereospecificity of Antineoplaston A10 Interaction with Double-stranded DNA. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

121 Ashraf, A.Q., Kampalath, B.N., Liau, M.C., Burzynski, S.R. Pharmacokinetic Study of Radioactive Antineoplaston A10 Following Oral Administration in Rats. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

122 Hendry, L.B., Muldoon, T.G., Burzynski, S.R., Copland, J.A., Lehner, A.F. Stereochemical Modeling Studies of the Interaction of Antineoplaston A10 with DNA. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

123 Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston Al 0 Injections. Presented at the 2nd Biennial Conference of Indian Society of Oncology; February, 1986; Bombay, India.

124 Burzynski, S.R., Lehner, A.F., Hendry, L.B. Putative Mechanism of Action of a Novel Peptide Analog with Apparent Antineoplastic Activity: Stereospecific interaction with DNA. Presented at the 13th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine; September, 1985; Paris, France.

125 Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Quantitative Assay of Plasma and Urinary Peptides as Aid for Evaluation of Cancer Patients Undergoing Antineoplaston Therapy. Presented at the 13th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine; September, 1985; Paris, France.

126 Hendry, L.B. Lehner, A.F., Burzynski, S.R. A Novel Naturally-occurring Peptide Analog with Apparent Antineoplastic Activity May Interact with DNA. Presented at the International Symposium, Cancer: Perspective for Control; August, 1985; Beijing, China.

127 Hendry, L.B., Lehner, A.F., Burzynski, S.R. Spectroscopic Studies of the Interaction of Antineoplaston A10 with DNA. Presented at the 12th Symposium of the International Association for Comparative Research on Leukemia and Related Disease; July, 1985; Hamburg, Germany.

128 Burzynski, S.R. Phase I Clinical Studies of Antineoplaston AS2-5 Iinjections. Presented at the 14th International Congress of Chemotherapy; June, 1985; Kyoto, Japan.

129 Burzynski, S.R., Burzynski, B., Mohabbat, M.O. Phase I Clinical Studies of Antineoplaston AS2-1 Injection. Presented at the 3rd European Conference on Clinical Oncology and Cancer Nursing; June, 1985; Stockholm, Sweden.

130 Liau, M.C., Burzynski, S.R. Alteration of Methylation Complex of Isoenzymes Critical to Malignant Evolution. Presented at the 12th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine, October, 1984; Houston, USA.

131 Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology Studies of Oral Formulation of Antineoplaston A10 in Cancer Patients. Presented at the 6th International Symposium on Future Trends in Chemotherapy; May, 1984; Pisa, Italy.

132 Lee, S. S., Mohabbat, M.O., Burzynski, S.R. Tissue Culture and Animal Toxicity Studies of Antineoplaston A2. Presented at the 6th International Symposium on Future Trends in Chemotherapy; May, 1984; Pisa, Italy.

133 Burzynski, S.R., Hendry, L.B., Mohabbat, M.O., Liau, M.C., Khalid, M., Burzynski, B. Purification, Structure Determination, Synthesis and Animal Toxicity Studies of Antineoplaston A10; PS 12.4.11-4. Presented at the 13th International Congress on Chemotherapy, TOM 17; August, 1983; Vienna, Austria.

134 Burzynski, S.R. Recent Advances in Ultramicroanalysis of Biologically Active Peptides. Presented at the 30th Southwest Regional American Chemical Society meeting, 1974; Houston, Texas.

135 Ungar, G., Burzynski, S.R. Detection of a Behavior-inducing Peptide (Scotophobin) in Brain by Ultramicroanalytical Method. Fed Proc., 1972; 31: 398.

136 Burzynski, S.R., Czerniak, Z. The Photometry of Negative Printed Chromatograms and its Application for Amino Acid Analysis in Human Blood. Biuletyn VII Ogolnopolskiej Konferencji Studenckich Kol Naukowych Akademii Medycznych; 1966; Poznan, Poland.

PATENTS

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
	AIDS			
Expired	**638869**		Australia	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**	ATE135,217	Austria	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		Belgium	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		Denmark	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		Europe	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		France	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**	69117923	Germany	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**	3019970	Greece	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		Italy	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		Luxembourg	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		Netherlands	Pharmaceutical compositions for use in treating AIDS.
Expired	**28633**		Philippines	Methods for treating AIDS.
Expired	**81889**		Singapore	Pharmaceutical compositions for use in treating AIDS.
Expired	**91/6977**		South Africa	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		Spain	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		Sweden	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		Switzerland	Pharmaceutical compositions for use in treating AIDS.
Expired	**0500905**		United Kingdom	Pharmaceutical compositions for use in treating AIDS.
Expired	**5089508**		USA	Methods for treating AIDS.
Expired	**5254587**		USA	Methods for treating AIDS.
	Aminocare			
	Pending		Arab Emirates	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	2002352843		Australia	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	Pending		Brazil	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
Expired	**2468133**		Canada	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	ZL02823606.8		China	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
	009516		Eurasia	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. The Eurasian patent has been validated in the following contracting countries: Azerbaijan (AZ), Kazahstan (KZ), and Russia (RU).
	1450781		Europe	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	1450781		France	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	1450781	DE60212393T2	Germany	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	Pending		Hungary	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	212246		India	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	ID0018257		Indonesia	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	1450781		Ireland	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	162141		Israel	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	4614660		Japan	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	247856		Mexico	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	532833		New Zealand	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	Pending		Norway	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	1-2004-500758		Philippines	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	953483		Republic of Korea	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	121173		Romania	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	104603		Singapore	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
Expired	**21542**		Slovenia	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	2004/4115		South Africa	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
	78977		Ukraine	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
Expired	**7427619132**		USA	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
	Atherosclerosis and Restenosis			
	757114		Australia	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1171110		Austria	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1171110		Belgium	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	2345409		Canada	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1171110		Europe	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	69916330T2		France	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1117110	69916330T2	Germany	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1045253		Hong Kong	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1171110		Ireland	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1171110		Italy	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
Expired	**4536258**		Japan	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1171110		Luxembourg	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1171110		Netherlands	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1171110	2219102	Spain	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1171110		Switzerland	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	1171110		United Kingdom	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
Expired	**6127419**		USA	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
	Autoimmune disease			
Expired	**656484**		Australia	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**	E162,714	Austria	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Belgium	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Denmark	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Europe	Compositions and methods for treating autoimmune diseases.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
Expired	**0603383**		France	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**	69316729.7	Germany	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**	980400879	Greece	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Ireland	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Italy	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Luxembourg	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Monaco	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Netherlands	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Portugal	Compositions and methods for treating autoimmune diseases.
Expired	**81891**		Singapore	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Spain	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Sweden	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		Switzerland	Compositions and methods for treating autoimmune diseases.
Expired	**0603383**		United Kingdom	Compositions and methods for treating autoimmune diseases.
Expired	**5646182**		USA	Methods for treating autoimmune diseases.
	Hypercholesterolemia			
	1206936		Europe	Phenylacetic acid compositions for treating or preventing hypercholesterolemia.
	1206936	60112872T2	Germany	Phenylacetic acid compositions for treating or preventing hypercholesterolemia.
	1048588		Hong Kong	Phenylacetic acid compositions for treating or preventing hypercholesterolemia.
	1206936		United Kingdom	Phenylacetic acid compositions for treating or preventing hypercholesterolemia.
	6,987,131		USA	Phenylacetic acid compositions for treating or preventing hypercholesterolemia.
	Liposomal Therapies			
	2254772		Canada	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.
	0906088		Europe	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.
	0906088		France	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.
	0906088	69734713.3-08	Germany	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.
	4320052		Japan	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
	0906088		United Kingdom	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.
Expired	**6013278**		USA	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.
	Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion			
Expired	**92391**		Finland	Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion.
Expired	**1562**		Kazakhstan	Compositions and methods for treating autoimmune diseases.
Expired	**5474**		Latvia	Compositions and methods for treating autoimmune diseases.
Expired	**3518**		Lithuania	Compositions and methods for treating autoimmune diseases.
Expired	**26099**		Philippines	Compositions and methods for treating autoimmune diseases.
Expired	**163552**		Poland	Compositions and methods for treating autoimmune diseases.
Expired	**139204**		Republic of Korea	Compositions and methods for treating autoimmune diseases.
Expired	**1809830**		Russia	Compositions and methods for treating autoimmune diseases.
Expired	**42331**		Taiwan	Compositions and methods for treating autoimmune diseases.
Expired	**15756**		Ukraine	Compositions and methods for treating autoimmune diseases.
Expired	**4918193**		USA	Methods for treating autoimmune diseases.
	Neoplastic disease / Purified			
Expired	**551109**		Australia	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**1188218**		Canada	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**162813**		Denmark	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**302/1989**		Hong Kong	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**65960**		Israel	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**2010265**		Japan	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**2010676**		Japan	Purified antineoplaston fractions.
Expired	**2057285**		Japan	Pharmaceutical compositions for neoplastic disease.
Expired	**MY102918A**		Malaysia	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**200805**		New Zealand	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**163595**		Norway	Purified antineoplaston fractions and methods of treating neoplastic disease.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
Expired	**82/4178**		SouthAfrica	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**512894**		Spain	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**4470970**		USA	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**4558057**		USA	Purified antineoplaston fractions and methods of treating neoplastic disease.
Expired	**4559325**		USA	Purified antineoplaston fractions and methods of treating neoplastic disease.
	Neurofibromatosis			
Expired	**683145**		Australia	Methods for treating neurofibromatosis.
Expired	**0680756**	E183,390	Austria	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Belgium	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Denmark	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Europe	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		France	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**	69511453.0	Germany	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Greece	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
	1016408		Hong Kong	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Ireland	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**	26583/BE/9	Italy	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Lithuania	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Luxembourg	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Monaco	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Netherlands	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Portugal	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
Expired	**0680756**		Slovenia	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**95/3500**		South Africa	Methods for treating neurofibromatosis.
Expired	**0680756**		Spain	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		Sweden	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
05/03/12	**0680756**		Switzerland	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**0680756**		United Kingdom	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
Expired	**5391575**		USA	Methods for treating neurofibromatosis.
	Parkinson's disease			
Expired	**638869**		Australia	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		Austria	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		Belgium	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		Denmark	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		Europe	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		France	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**	69114261.0	Germany	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**	3018437	Greece	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**	19057/BE/96	Italy	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		Luxembourg	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		Netherlands	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**28633**		Philippines	Methods for treating Parkinson's disease.
Expired	**91/6977**		South Africa	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		Spain	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		Sweden	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		Switzerland	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**0500905**		United Kingdom	Pharmaceutical compositions for use in treating Parkinson's disease.
Expired	**5089508**		USA	Methods for treating Parkinson's disease.
	Pharmaceutical composition comprising phenylacetylglutamine, etc.			
Expired	**0069232**	E23113	Austria	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
Expired	**0069232**		Belgium	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.
Expired	**1262907**		Canada	3-[N-Phenylacetylaminopiperidine]-2,6-dione and Process of Synthesizing Same.
Expired	**0069232**		Europe	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.
Expired	**0069232**		France	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.
Expired	**0069232**	P3273952.4	Germany	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.
Expired	**0069232**	22434/BE/86	Italy	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.
Expired	**0069232**		Luxembourg	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.
Expired	**0069232**		Netherlands	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.
Expired	**0069232**		Sweden	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.
Expired	**0069232**		Switzerland	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.
Expired	**0069232**		United Kingdom	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)-piperidine-2,6-dione.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
	Skin			
Expired	**0197358**		Austria	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**0197358**		Belgium	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**1262866**		Canada	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation.
Expired	**0197358**		Europe	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**0197358**		France	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**0197358**		Germany	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**0197358**		Italy	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**1953215**		Japan	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**0197358**		Luxembourg	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**0197358**		Netherlands	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**0197358**		Sweden	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**0197358**		Switzerland	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**0197358**		United Kingdom	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin.
Expired	**4593038**		USA	Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation.
	Synthesis of 4-phenylbutyric acid.			
	2447803		Canada	Synthesis of 4-phenylbutyric acid.
	ZL02810264.9		China	Synthesis of 4-phenylbutyric acid.
	1404638		Europe	Synthesis of 4-phenylbutyric acid. The European patent has been validated in the following contracting countries: Belgium (BE), Cyprus (CY), **Germany (DE), France (FR), United Kingdom (GB), Ireland (IE)**, Liechtenstein (LI), Monaco (MC), Republic of Turkey (TR).
	1065996		Hong Kong	Synthesis of 4-phenylbutyric acid.
	Pending	P0400053	Hungary	Synthesis of 4-phenylbutyric acid.
	229199		India	Synthesis of 4-phenylbutyric acid.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
	158914		Israel	Synthesis of 4-phenylbutyric acid.
	4338401		Japan	Synthesis of 4-phenylbutyric acid.
	201802	P364646	Poland	Synthesis of 4-phenylbutyric acid.
	10-0905139		Republic of Korea	Synthesis of 4-phenylbutyric acid.
	2297998		Russia	Synthesis of 4-phenylbutyric acid.
	0101088		Singapore	Synthesis of 4-phenylbutyric acid.
	6372938 B1		USA	Synthesis of 4-phenylbutyric acid.
	Testing procedure to aid diagnosis of cancer and evaluate the progress of cancer therapy			
Expired	**4444890**		USA	Testing procedure to aid diagnosis of cancer and evaluate the progress of cancer therapy.
	Toothpaste			
	7087219		USA	Toothpaste Containing Anticancer Agents.
	Treatment of Neoplastic Disease			
	1098643		Austria	Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.
	ZL200410061600.5		China	A composition for treating neoplastic disease and the use thereof.
	1098643		Europe	Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.
	1098643		Finland	Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.
	1098643		France	Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.
	1098643	69914084.6-08	Germany	Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.
	227008		India	A Phamaceutical Composition Comprising Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the Treatment of Neoplastic Disease.
	509244		New Zealand	A Phamaceutical Composition Comprising Phenylacetate and Phenylacetylglutamine.
	0414587		Republic of Korea	A Phamaceutical Composition Comprising Phenylacetate and Phenylacetylglutamine.
	0417100		Republic of Korea	A Phamaceutical Composition Comprising Phenylacetate and Phenylacetylisoglutamine.
	0417101		Republic of Korea	A Pharmaceutical Composition Comprising an Aqueous Solution of Phenylacetate.

Treatment Regimen

759278	Australia	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
	1098643		Belgium	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	2336945		Canada	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	ZL99811314.X		China	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	1098643		Denmark	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	004179		Eurasia	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. The Eurasian patent has been validated in the following contracting countries: Azerbaijan, Armenia, Belarus, Kazakhstan, Kyrgyzstan, Moldova, and **The Russian Federation**.
	1098643		Greece	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	01107897.8		Hong Kong	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	ID0012068		Indonesia	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	ID0013227		Indonesia	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	140848		Israel	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	1098643		Italy	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	1098643		Latvia	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	1098643		Luxembourg	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
Expired	**222968**		Mexico	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	1098643		Netherlands	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	509244		New Zealand	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	1098643		Portugal	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	399658		Republic of Korea	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

	78643		Singapore	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	2001/0622		South Africa	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	1098643	2214866	Spain	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
	1098643		Sweden	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	1098643		Switzerland	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	1098643		United Kingdom	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
Expired	**6258849**		USA	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
Expired	**6943192B2**		USA	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
	VHL			
	012908		Eurasia	Method for treatment of Von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives. The Eurasian patent has been validated in the following contracting countries: Azerbaijan (AZ), Kazakhstan (KZ), and Russia (RU).
	1855665		Europe	Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.
	1855665		Germany	Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.
	1855665		United Kingdom	Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.
	Viral infections			
Expired	**0601164**		Austria	Methods for treating viral infections.
Expired	**0601164**		Belgium	Methods for treating viral infections.
Expired	**0601164**		Denmark	Methods for treating viral infections.
Expired	**0601164**		Europe	Methods for treating viral infections.
Expired	**0601164**		France	Methods for treating viral infections.
Expired	**0601164**	69327642.8	Germany	Methods for treating viral infections.
Expired	**0601164**		Greece	Methods for treating viral infections.
Expired	**0601164**		Ireland	Methods for treating viral infections.
Expired	**0601164**		Italy	Methods for treating viral infections.
Expired	**0601164**		Luxembourg	Methods for treating viral infections.

Expired	**0601164**		Monaco	Methods for treating viral infections.
Expired	**0601164**		Netherlands	Methods for treating viral infections.
Expired	**0601164**		Portugal	Methods for treating viral infections.
Expired	**67344**		Singapore	Methods for treating viral infections.
Expired	**0601164**		Spain	Methods for treating viral infections.

Expired	*Patent No.*	*National Patent No.*	*Country*	*Title*
Expired	**0601164**		Sweden	Methods for treating viral infections.
Expired	**0601164**		Switzerland	Methods for treating viral infections.
Expired	**0601164**		United Kingdom	Methods for treating viral infections.
Expired	**5244922**		USA	Methods for treating viral infections.

Trade Name

Tradename No.	*Country*	*Title*
Reg.No.: CDN-HY-07011055; (56); (57).	China	China Domain Name Registration Certificate. Internet Keyword: Aminocare. Valid until: 5/23/2017 China Domain Name Registration Certificate. Internet Keyword: Aminocare.cn. Valid until: 5/23/2012 China Domain Name Registration Certificate. Internet Keyword: Aminocare.com.cn. Valid until: 5/23/2012

Trademarks

Trademark No.	*Country/State*	*Title*
46957304	China	Aminocare
004006102	Europe	Fengenal in Class 5
004006334	Europe	Avavital
004006359	Europe	Bugenal in Class 5
004006375	Europe	Lubgen Farma in Classes 39 (distribution of pharmaceutical preparation) and in Class 40 (custom manufacturing of pharmaceutical preparations for others)
004006425	Europe	Cengenal in Class 5
004006664	Europe	Astugenal in Class 5
004006979	Europe	Atengenal in Class 5
300343377	Hong Kong	Aminocare in Class 5
188750	Poland	Lubgen Farma
120234	Republic of Korea	Lubgen Farma in Class 35 (Arranging of pharmaceutical sales)
129501	Republic of Korea	Lubgen Farma in Class 40 (custom manufacturing of pharmaceutical preparations for others)
620203	Republic of Korea	Bugenal in Class 5
622094	Republic of Korea	Astugenal in Class 5
622095	Republic of Korea	Atengenal in Class 5
622096	Republic of Korea	Avavital in Class 5
622097	Republic of Korea	Cengenal in Class 5
622098	Republic of Korea	Fengenal in Class 5
292206	Russia	Astugenal in Class 5
293368	Russia	Bugenal in Class 5
300114	Russia	Cengenal in Class 5
304514	Russia	Lubgen Farma in Class 35 (Arranging of pharmaceutical sales) and in Class 40 (custom manufacturing of pharmaceutical preparations for others)

Trademark No.	*Country*	*Title*
304679	Russia	Avavital in Class 5
304680	Russia	Atengenal in Class 5
304681	Russia	Fengenal in Class 5
327323	Russia	Aminocare in Class 5
01165897	Taiwan	Aminocare in Class 5
050590	USA	State Trademark 'Antineoplaston' - Texas
1719793	USA	Federal trademark 'Antineoplaston' for pharmaceuticals.
2999213	USA	Bugenal in Class 5
3142996	USA	Ampolgen Pharmaceuticals, LLC. In Classes 35 and 42.
3160376	USA	Aminocare in Class 6
3169436	USA	Avavital in Class 5
3174860	USA	Fengenal in Class 5
3177785	USA	Astugenal in Class 5
318432	USA	Atengenal in Class 5
3276180	USA	Cengenal in Class 5